Genscript Biotech Stock Today
| GNNSF Stock | USD 1.38 0.01 0.72% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Genscript Biotech is trading at 1.38 as of the 23rd of November 2024. This is a 0.72% down since the beginning of the trading day. The stock's lowest day price was 1.38. Genscript Biotech has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Genscript Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of November 2023 and ending today, the 23rd of November 2024. Click here to learn more.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. The company has 2.12 B outstanding shares. More on Genscript Biotech
Moving against Genscript Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genscript Pink Sheet Highlights
| Vice President - Strategy | Li Zhu |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Genscript Biotech [GNNSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.67 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genscript Biotech's market, we take the total number of its shares issued and multiply it by Genscript Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genscript Biotech classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 2.12 B outstanding shares.
Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Genscript Biotech Probability Of Bankruptcy
Ownership AllocationGenscript Biotech has a total of 2.12 Billion outstanding shares. Genscript Biotech secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genscript Ownership Details
Genscript Biotech Risk Profiles
| Mean Deviation | 0.7645 | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.39 | |||
| Risk Adjusted Performance | (0.07) |
Genscript Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genscript Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Genscript Biotech Corporate Management
| Shiniu Wei | Chief Officer | Profile | |
| Brian Min | CEO Bus | Profile | |
| Zhenyu Liu | Chief Officer | Profile | |
| Weihui Shao | Chief Officer | Profile | |
| Chifa Zhang | Department head - industry synthetic biology product segment | Profile |
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.